BAX - Baxter International Inc.
| Previous Close | 66.98 |
| Open | 67.06 |
| Bid | 67.18 x 100 |
| Ask | 67.19 x 100 |
| Day's Range | 66.95 - 67.40 |
| 52 Week Range | 52.59 - 72.58 |
| Volume | 543,684 |
| Avg. Volume | 3,223,148 |
| Market Cap | 36.017B |
| Beta | 1.07 |
| PE Ratio (TTM) | 52.04 |
| EPS (TTM) | 1.29 |
| Earnings Date | Apr 26, 2018 |
| Forward Dividend & Yield | 0.64 (0.97%) |
| Ex-Dividend Date | 2018-03-01 |
| 1y Target Est | 75.71 |
- Zacks•3 days ago
Can Hospital-Products Unit Aid Baxter (BAX) in Q1 Earnings?
Positive tidings on regulatory front, expanding Hospital-Products portfolio, strategic collaborations and strong presence in the international markets are key positives for Baxter's (BAX) Q1 results.
- Zacks•4 days ago
Zacks.com highlights: Baxter International, Copart, Applied Materials and Steel Dynamics
Zacks.com highlights: Baxter International, Copart, Applied Materials and Steel Dynamics
- Zacks•7 days ago
4 Top Stocks to Buy With Superb Efficiency Level
Favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with its price performance
- Thomson Reuters StreetEvents•10 days ago
Edited Transcript of BAX presentation 7-Mar-17 12:30pm GMT
Baxter International Inc at Raymond James Institutional Investors Conference
- Market Realist•10 days ago
Abbott Laboratories Goes Ex-Dividend on April 12, 2018
The dividend will be payable on May 15, 2018, to shareholders of record on April 13, 2018. Abbott Laboratories is part of the S&P 500 Dividend Aristocrats, which are the companies that have paid out consistently increasing dividends to shareholders for at least 25 consecutive years. As of April 6, 2018, ABT stock has a dividend yield of 1.9%.
Markit•10 days agoSee what the IHS Markit Score report has to say about Baxter International Inc.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BAX. Over the last one-month, outflows of investor capital in ETFs holding BAX totaled $16.11 billion.
Market Realist•14 days agoVarian Medical Systems: Expanding in Proton Therapy
Should Investors Be Interested in Varian Medical Systems?
- Business Wire•16 days ago
Baxter to Host First Quarter 2018 Financial Results Conference Call for Investors
Baxter International Inc. , will host a conference call to discuss its first quarter 2018 financial results on Thursday, April 26, 2018, at 7:30 a.m. Central Daylight Time.
- Business Wire•18 days ago
Baxter International Inc. to Host Webcast of Annual Meeting of Stockholders
Baxter International Inc. will host a webcast of its Annual Meeting of Stockholders on Tuesday, May 8, 2018 at 9:00 a.m. Central Time.
Market Realist•21 days agoDiscussing BDX’s Recent Stock Price Performance
BDX's March 2018 Performance, Recommendations, and Updates
- Moody's•22 days ago
Baxter International Inc. -- Moody's upgrades Baxter International to Baa1 from Baa2, stable outlook
Moody's Investors Service, ("Moody's") upgraded Baxter International Inc.'s ("Baxter") senior unsecured rating to Baa1 from Baa2. Moody's also affirmed the company's Prime-2 commercial ...
- Zacks•22 days ago
Top Analyst Reports for Netflix, PNC Financial & Mondelez
Top Analyst Reports for Netflix, PNC Financial & Mondelez
Market Realist•23 days agoBaxter International Created a New Reporting Structure for 2018
Who Is Watching Baxter International in March 2018? For fiscal 2018, Baxter International (BAX) changed its reporting structure from the previous year. The company has two segments—Hospital Products and Renal—with a range of one to six global businesses.
Market Realist•23 days agoBaxter International’s 2018 Revenues Expected to See Modest Rise
Who Is Watching Baxter International in March 2018? For fiscal 2017, Baxter International (BAX) reported revenues of ~$10.6 billion, which represents 4.0% YoY growth on a reported basis and a 5.0% rise on an operational basis. The company has projected its annual revenues for 2018 to be 6.0%–7.0% higher year-over-year (or YoY) on a reported basis.
Market Realist•24 days agoAnalysts’ March 2018 Ratings for Baxter International and Peers
Who Is Watching Baxter International in March 2018? Baxter International’s (BAX) top-line performance in 4Q17 was mainly driven by increased demand for the company’s Fluid Systems’ products. Baxter International also witnessed rising demand for its cytotoxic contract manufacturing services.
- Simply Wall St.•24 days ago
What Do Analysts Think About The Future Of Baxter International Inc’s (NYSE:BAX)?
In December 2017, Baxter International Inc (NYSE:BAX) released its most recent earnings update. Generally, analysts seem highly optimistic, with profits predicted to ramp up by an impressive 90.05% next year,Read More...
- Zacks•24 days ago
Baxter (BAX) Banks on Portfolio Strength, Strategic Buyouts
Baxter (BAX) gains on a slew of regulatory approvals and strategic collaborations.
- Zacks•25 days ago
Top Analyst Reports for Nike, Eli Lilly & NVIDIA
Top Analyst Reports for Nike, Eli Lilly & NVIDIA
Markit•25 days agoSee what the IHS Markit Score report has to say about Baxter International Inc.
Baxter International Inc NYSE:BAX
- Market Realist•28 days ago
Baxter International Completes Its Mallinckrodt Assets Buy
Baxter International (BAX) announced the completion of its acquisition of Recothrom and Preveleak assets from Mallinckrodt Pharmaceuticals (MNK) for a total consideration of $185.0 million. This transaction includes $153.0 million in upfront payments and the rest in future milestone-based payments. Additionally, Baxter International has assumed Preveleak’s associated expenses and the contingent liabilities. Preveleak’s manufacturing operations are also included in the deal.
Markit•28 days agoSee what the IHS Markit Score report has to say about Baxter International Inc.
Baxter International Inc NYSE:BAX
- Zacks•29 days ago
Baxter (BAX) Closes Acquisition of RECOTHROM & PREVELEAK
Baxter (BAX) steadily focuses on improving its Advanced Surgery business.
- Zacks•last month
Here's Why You Should Invest in Baxter International Now
Recent buyouts and positive regulatory tidings boost investors' confidence on Baxter International (BAX).
Market Realist•last monthWhat Investors Should Know about TMO’s Dividends
What Analysts Recommend for Thermo Fisher Scientific
